Difference between revisions of "UPICT TEST SITE - Modified"
Line 11: | Line 11: | ||
:1.3. Relationship with other diagnostic methods | :1.3. Relationship with other diagnostic methods | ||
:1.4. Covariates (note – please see full FDG-PET document; should this material be in other sections of the document?) | :1.4. Covariates (note – please see full FDG-PET document; should this material be in other sections of the document?) | ||
− | 2. Claims (what users will be able to achieve) | + | '''2. Claims (what users will be able to achieve)''' |
:2.1 Claim #1: | :2.1 Claim #1: | ||
:2.2. Claim #2: | :2.2. Claim #2: | ||
Line 17: | Line 17: | ||
:2.4. Claim #4: | :2.4. Claim #4: | ||
:2.5. Claim #5: (etc.) | :2.5. Claim #5: (etc.) | ||
− | 3. Imaging Protocol: Overview | + | '''3. Imaging Protocol: Overview''' |
:3.1. Detail: Utilities and Endpoints of the Imaging Protocol within the Clinical Trial | :3.1. Detail: Utilities and Endpoints of the Imaging Protocol within the Clinical Trial | ||
:3.2. Detail: Management of Pre-enrollment Imaging Tests | :3.2. Detail: Management of Pre-enrollment Imaging Tests | ||
Line 24: | Line 24: | ||
:3.5. Detail: Management of Off-protocol Imaging | :3.5. Detail: Management of Off-protocol Imaging | ||
:3.6. Detail: Subject Selection Criteria Related to Imaging (mainly exclusionary in nature) | :3.6. Detail: Subject Selection Criteria Related to Imaging (mainly exclusionary in nature) | ||
− | 4. Subject Preparation | + | '''4. Subject Preparation''' |
:4.1. Detail: Interval Timing (e.g., oral and/or IV intake, vigorous physical activity, timing relative to non-protocol-related medical interventions, etc.) | :4.1. Detail: Interval Timing (e.g., oral and/or IV intake, vigorous physical activity, timing relative to non-protocol-related medical interventions, etc.) | ||
:4.2. Detail: Specific Pre-imaging Instructions | :4.2. Detail: Specific Pre-imaging Instructions | ||
:4.3. Detail: Prior to Arrival | :4.3. Detail: Prior to Arrival | ||
:4.4. Detail: Upon Arrival (including ancillary testing associated with the imaging and downstream actions relative to such testing) | :4.4. Detail: Upon Arrival (including ancillary testing associated with the imaging and downstream actions relative to such testing) | ||
− | 5. Imaging Procedures: General | + | '''5. Imaging Procedures: General''' |
:5.1. Detail: Data that should accompany the request for a PET study | :5.1. Detail: Data that should accompany the request for a PET study | ||
:5.2. Detail: Imaging Agent Preparation and Specification (Contrast agent or radiopharmaceutical) | :5.2. Detail: Imaging Agent Preparation and Specification (Contrast agent or radiopharmaceutical) | ||
Line 39: | Line 39: | ||
:5.8. Detail: Instructions to Subject during Acquisition (e.g., breathing) | :5.8. Detail: Instructions to Subject during Acquisition (e.g., breathing) | ||
:5.9. Detail: Timing (e.g., relative to previously administered imaging agents / enhancers; inter-time point standardization) | :5.9. Detail: Timing (e.g., relative to previously administered imaging agents / enhancers; inter-time point standardization) | ||
− | 6. Reconstruction and Reporting | + | '''6. Reconstruction and Reporting''' |
:6.1. Detail: Reconstruction | :6.1. Detail: Reconstruction | ||
:6.2. Detail: Reporting | :6.2. Detail: Reporting | ||
:6.3. Detail: Interpretation and pitfalls | :6.3. Detail: Interpretation and pitfalls | ||
− | 7. Archival Requirements for Primary Source Imaging Data | + | '''7. Archival Requirements for Primary Source Imaging Data''' |
:7.1. Detail: Data should be archived in DICOM 3.0 format or the current version of DICOM recommended by XXX WG YY of the XXX. | :7.1. Detail: Data should be archived in DICOM 3.0 format or the current version of DICOM recommended by XXX WG YY of the XXX. | ||
:7.2. Detail: De-identification / Anonymization Schema(s) to Be Used | :7.2. Detail: De-identification / Anonymization Schema(s) to Be Used | ||
Line 50: | Line 50: | ||
:7.5. Detail: Requirements for Local Retention of Imaging Data | :7.5. Detail: Requirements for Local Retention of Imaging Data | ||
:7.6. Detail: Requirements for Central Management of Imaging Data and Imaging Metadata (e.g., the results of image analysis) | :7.6. Detail: Requirements for Central Management of Imaging Data and Imaging Metadata (e.g., the results of image analysis) | ||
− | 8. Post-processing (i.e., anything not done on an acquisition platform that affects DICOM image data and/or pixel / voxel values) | + | '''8. Post-processing (i.e., anything not done on an acquisition platform that affects DICOM image data and/or pixel / voxel values)''' |
None prior to importation into free standing image analysis software package | None prior to importation into free standing image analysis software package | ||
− | 9. Interpretation | + | '''9. Interpretation''' |
:9.1. Detail: Image quality assessment to confirm correctness and completeness of image submission | :9.1. Detail: Image quality assessment to confirm correctness and completeness of image submission | ||
:9.2. Detail: Volume of interest (VOI) Definition | :9.2. Detail: Volume of interest (VOI) Definition | ||
:9.3. Detail: Timepoint exams defined by charter re: exam types and dates of inclusion | :9.3. Detail: Timepoint exams defined by charter re: exam types and dates of inclusion | ||
:9.4. Detail: @Open next timepoint for given subject | :9.4. Detail: @Open next timepoint for given subject | ||
− | 10. Radiation Dose and Safety Considerations | + | '''10. Radiation Dose and Safety Considerations''' |
− | 11. Quality Control | + | '''11. Quality Control''' |
:11.1. Detail: General | :11.1. Detail: General | ||
:11.2. Detail: Quality Control and Inter-institution Cross-Calibration | :11.2. Detail: Quality Control and Inter-institution Cross-Calibration | ||
− | 12. Required Documentation | + | '''12. Required Documentation''' |
:12.1. Detail: Subject preparation | :12.1. Detail: Subject preparation | ||
:12.2. Detail: Imaging agent dose calculation | :12.2. Detail: Imaging agent dose calculation | ||
Line 69: | Line 69: | ||
:12.6. Detail: Image analysis and interpretation | :12.6. Detail: Image analysis and interpretation | ||
:12.7. Detail: Site selection and Quality Control | :12.7. Detail: Site selection and Quality Control | ||
− | 13. Acknowledgements | + | '''13. Acknowledgements''' |
Revision as of 18:22, 29 June 2009
FDG-PET/CT draft template GSD, June 29, 2009
FYI: The complete draft of the QIBA FDG-PET/CT Whole Body protocol is posted at http://qibawiki.rsna.org/index.php?title=Profile:_FDG-PET_Whole_Body
1. Executive Summary, Introduction and Background Information
- 1.1. Principle
- 1.2. Indications
- 1.3. Relationship with other diagnostic methods
- 1.4. Covariates (note – please see full FDG-PET document; should this material be in other sections of the document?)
2. Claims (what users will be able to achieve)
- 2.1 Claim #1:
- 2.2. Claim #2:
- 2.3. Claim #3:
- 2.4. Claim #4:
- 2.5. Claim #5: (etc.)
3. Imaging Protocol: Overview
- 3.1. Detail: Utilities and Endpoints of the Imaging Protocol within the Clinical Trial
- 3.2. Detail: Management of Pre-enrollment Imaging Tests
- 3.3. Detail: Timing of Imaging Tests within the Clinical Trial Calendar
- 3.4. Detail: Management of On-protocol Imaging Performed Off-schedule
- 3.5. Detail: Management of Off-protocol Imaging
- 3.6. Detail: Subject Selection Criteria Related to Imaging (mainly exclusionary in nature)
4. Subject Preparation
- 4.1. Detail: Interval Timing (e.g., oral and/or IV intake, vigorous physical activity, timing relative to non-protocol-related medical interventions, etc.)
- 4.2. Detail: Specific Pre-imaging Instructions
- 4.3. Detail: Prior to Arrival
- 4.4. Detail: Upon Arrival (including ancillary testing associated with the imaging and downstream actions relative to such testing)
5. Imaging Procedures: General
- 5.1. Detail: Data that should accompany the request for a PET study
- 5.2. Detail: Imaging Agent Preparation and Specification (Contrast agent or radiopharmaceutical)
- 5.3. Detail: Contrast administration: (agent, dose, route)
- 5.4. Detail: Procedure for performing the PET study
- 5.5. Detail: Protocol alterations permitted in the case of multi-centre studies
- 5.6. Detail: Imaging Data Acquisition
- 5.7. Detail: Subject Positioning
- 5.8. Detail: Instructions to Subject during Acquisition (e.g., breathing)
- 5.9. Detail: Timing (e.g., relative to previously administered imaging agents / enhancers; inter-time point standardization)
6. Reconstruction and Reporting
- 6.1. Detail: Reconstruction
- 6.2. Detail: Reporting
- 6.3. Detail: Interpretation and pitfalls
7. Archival Requirements for Primary Source Imaging Data
- 7.1. Detail: Data should be archived in DICOM 3.0 format or the current version of DICOM recommended by XXX WG YY of the XXX.
- 7.2. Detail: De-identification / Anonymization Schema(s) to Be Used
- 7.3. Detail: Archival and Transmission of Image Data
- 7.4. Detail: Transmission of Imaging Data from Sites to Central Archive
- 7.5. Detail: Requirements for Local Retention of Imaging Data
- 7.6. Detail: Requirements for Central Management of Imaging Data and Imaging Metadata (e.g., the results of image analysis)
8. Post-processing (i.e., anything not done on an acquisition platform that affects DICOM image data and/or pixel / voxel values) None prior to importation into free standing image analysis software package 9. Interpretation
- 9.1. Detail: Image quality assessment to confirm correctness and completeness of image submission
- 9.2. Detail: Volume of interest (VOI) Definition
- 9.3. Detail: Timepoint exams defined by charter re: exam types and dates of inclusion
- 9.4. Detail: @Open next timepoint for given subject
10. Radiation Dose and Safety Considerations 11. Quality Control
- 11.1. Detail: General
- 11.2. Detail: Quality Control and Inter-institution Cross-Calibration
12. Required Documentation
- 12.1. Detail: Subject preparation
- 12.2. Detail: Imaging agent dose calculation
- 12.3. Detail: Imaging agent-related
- 12.4. Detail: Image data acquisition-related
- 12.5. Detail: Inherent image data reconstruction / processing
- 12.6. Detail: Image analysis and interpretation
- 12.7. Detail: Site selection and Quality Control
13. Acknowledgements